CN-120775729-B - Lactobacillus helveticus for producing DPP-IV inhibitory peptide and blood glucose reducing goat milk and preparation method thereof

CN120775729BCN 120775729 BCN120775729 BCN 120775729BCN-120775729-B

Abstract

The invention discloses a lactobacillus helveticus producing DPP-IV inhibitory peptide, and a hypoglycemic goat milk and a preparation method thereof, wherein goat milk is taken as a raw material, lactobacillus helveticus KD12 producing DPP-IV inhibitory peptide is adopted to ferment goat milk, so that the hypoglycemic lactobacillus fermented goat milk containing DPP-IV inhibitory peptide is obtained, and the fermented goat milk is dried to prepare the hypoglycemic lactobacillus fermented goat milk powder containing DPP-IV inhibitory peptide. Inactivating lactobacillus of the blood glucose reducing lactobacillus fermented goat milk to obtain blood glucose reducing metacarpal milk, concentrating, and drying to obtain blood glucose reducing metacarpal milk powder. The hypoglycemic goat milk provided by the invention has higher DPP-IV inhibition rate, can be used for inhibiting DPP-IV activity after being eaten by consumers so as to reduce blood sugar and reduce the dosage of hypoglycemic agents, thereby reducing side effects caused by the hypoglycemic agents.

Inventors

SHU GUOWEI
ZHANG ZONGCAI
XU LIHAO
ZHENG QIQI
Lei huan
ZHANG LUYAO
XIE ZIPEI

Assignees

陕西科技大学

Dates

Publication Date: 20260512
Application Date: 20250707

Claims (5)

1. The lactobacillus helveticus KD12 is characterized in that the classification name is Lactobacillus helveticus, the strain is preserved in China center for type culture collection (China center for type culture collection) in the 9 th month and 14 th year of 2024, and the preservation number is CCTCC NO: M20241994.
2. The lactobacillus helveticus KD12 according to claim 1, wherein the nucleotide sequence of the 16s rDNA of the lactobacillus helveticus KD12 is shown in SEQ ID No. 1.
3. The lactic acid bacteria fermented goat milk powder for reducing blood sugar is characterized in that the lactic acid bacteria fermented goat milk for reducing blood sugar is obtained by fermenting goat milk with the Lactobacillus helveticus KD12 according to claim 1 or 2, the lactic acid bacteria fermented goat milk for reducing blood sugar is dried to obtain the lactic acid bacteria fermented goat milk powder for reducing blood sugar, the viable count of the Lactobacillus helveticus KD12 in the lactic acid bacteria fermented goat milk powder for reducing blood sugar is 1.68 multiplied by 10 7 CFU/g~1.47×10 9 CFU/g, and the DPP-IV inhibition rate is 27.87% -85.75%.
4. The method for preparing the hypoglycemic lactobacillus fermented goat milk powder according to claim 3, wherein the hypoglycemic lactobacillus fermented goat milk powder is obtained by directly spray-drying or vacuum freeze-drying at high temperature.
5. The method for preparing the hypoglycemic lactobacillus fermented goat milk powder according to claim 3, wherein prebiotics and full-fat goat milk powder are added into the hypoglycemic lactobacillus fermented goat milk, and the hypoglycemic lactobacillus fermented goat milk powder is obtained by high-temperature spray drying or vacuum low-temperature spray drying after uniform mixing.

Description

Lactobacillus helveticus for producing DPP-IV inhibitory peptide and blood glucose reducing goat milk and preparation method thereof Technical Field The invention belongs to the technical field of fermentation engineering, and in particular relates to lactobacillus helveticus for producing DPP-IV inhibitory peptide and a hypoglycemic goat milk and a preparation method thereof. Background Insulin is a hormone for regulating blood sugar, and when the pancreas does not produce enough insulin or the human body cannot effectively utilize the produced insulin, the blood sugar level is in a state exceeding a normal value, and diabetes is developed over time. Diabetes causes serious damage to many systems of the human body, especially nerves and blood vessels. Type II diabetics account for about 90% of the total diabetics and are mainly characterized by insulin resistance. The oral hypoglycemic agent for type II diabetes comprises dipeptidyl peptidase-IV (DIPEPTIDYL PEPTIDASE IV, DPP-IV) inhibitor, such as sitagliptin, saxagliptin, alogliptin, etc. DPP-IV is a serine protease that is widely distributed in human tissue. It is responsible for the degradation and inactivation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin polypeptide (GIP). DPP-IV inhibitors can enhance GLP-1 and GIP activities, stimulate insulin secretion, and regulate blood glucose levels. Inhibition of DPP-IV is a key strategy for the effective treatment of type II diabetes; Although the pharmacological treatment has good control effect on blood sugar, there are many side effects such as significant changes in body weight, osteoporosis, gastrointestinal dysfunction and increased risk of cardiovascular diseases, so that food-derived DPP-IV inhibitory peptides, which are peptide fragments capable of reducing DPP-IV activity, have been attracting attention, and although the amino acid sequence and the peptide fragment lengths are different, they are capable of reducing blood sugar, and are also called as hypoglycemic peptides. Compared with chemically synthesized medicines, the food-borne hypoglycemic peptide has higher safety. The existing goat milk products mainly comprise infant formula goat milk powder, prepared goat milk powder, pure goat milk, acid goat milk and a small amount of milk beverage, and the products are seriously homogenized and are highly competitive, so that the development of the hypoglycemic goat milk products with DPP-IV inhibiting activity by adopting the lactic acid bacteria producing the DPP-IV inhibiting peptide is necessary. Disclosure of Invention In order to solve the problems in the prior art, the invention provides lactobacillus helveticus for producing DPP-IV inhibitory peptide, and a hypoglycemic goat milk and a preparation method thereof. Fresh goat milk or reconstituted goat milk is used as a raw material, lactobacillus helveticus KD12 for producing DPP-IV inhibitory peptide is used for fermenting the goat milk, protein in the goat milk is decomposed into peptide for inhibiting DPP-IV, so that the hypoglycemic lactobacillus fermented goat milk containing the DPP-IV inhibitory peptide is obtained, the hypoglycemic metazoar goat milk is obtained after lactobacillus inactivation, nutrition enhancers are added and concentrated, the hypoglycemic metazoar goat milk powder is obtained after spray drying, the DPP-IV inhibitory peptide is separated, purified and identified by amino acid sequence, the position of the DPP-IV inhibitory peptide in the goat milk protein is determined, and the hypoglycemic lactobacillus fermented goat milk powder containing the DPP-IV inhibitory peptide is prepared by drying the fermented goat milk. In order to achieve the aim, the invention provides the following technical scheme that lactobacillus helveticus KD12 for producing DPP-IV inhibitory peptide is classified and named Lactobacillus helveticus, and the strain is preserved in China Center for Type Culture Collection (CCTCC) with the preservation number of M20241994 in 9 months and 14 days of 2024. Further, the base pair sequence of the Lactobacillus helveticus KD12 is shown as a sequence 1. The invention also provides the hypoglycemic lactobacillus fermented goat milk, wherein the lactobacillus helveticus KD12 fermented goat milk is used for obtaining the goat milk containing the DPP-IV inhibitory peptide, namely the hypoglycemic lactobacillus fermented goat milk, and the DPP-IV inhibitory rate is 68.23% -92.72%. Furthermore, amino acid sequences of DPP-IV inhibitory peptide in the goat milk fermented with the hypoglycemic lactobacillus are shown as sequences 2-13:FPKYP, AGPFTPT, AIPY, KYIPIQY, VLPVPQ, VLGP, LKALP, GKNKSQS, IRISHEL, FSDIPNP and PVPQ. Further, the inoculation amount of the lactobacillus helveticus KD12 is 0.01% -0.05%, the fermentation time is 18-24 h, and the fermentation temperature is 34-40 ℃. The invention also provides the hypoglycemic lactobacillus fermented goat milk powder, which is prepared by dr